Title: Anti-HIV and anti-inflammatory action of iodine-lithium-α-dextrin is accompanied by the improved quality of life in AIDS patients
Authors: Levon M. Mkhitaryan, Tigran K. Davtyan, Emil S. Gabrielyan, Levon A. Gevorkyan
Addresses: Laboratory of Immunology and Virology, Armenicum Research Center, CJSC Armenicum+, 37 Nalbandyan Street, Yerevan 375001, Republic of Armenia. ' Laboratory of Immunology and Virology, Armenicum Research Center, CJSC Armenicum+, 37 Nalbandyan Street, Yerevan 375001, Republic of Armenia. ' Drug and Medical Technology Agency of Ministry of Health, Yerevan, Republic of Armenia. ' CJSC Armenicum+, 37 Nalbandyan Street, Yerevan 375001, Republic of Armenia
Abstract: Clinical efficacy, tolerability and safety of various doses of Iodine-Lithium-α-Dextrin (ILαD) monotherapy have been evaluated in 56 HIV-infected patients enrolled in double blind uncontrolled randomised study during 48 weeks follow-up period. ILαD was administered intravenously three times over five days with intervals of 2–3 weeks between treatments for a total of 12 infusions in 4 cycles. HIV-1 RNA reduction and increase of CD4+ T-cell counts as well as decrease of serum levels of IgG, IgA, β2 microglobulin, tumour necrosis factor-α and soluble interleukin-2 receptor were observed on 4–24th weeks. Quality of life was dramatically improved on 4–48th weeks and more. The side-effects were phlebitis of punctured small veins and subfebrile fever, that did not lead to discontinuation of the treatment and did not require special treatment. ILαD appears to be safe and can be used as an adjuvant therapy for long term improvement of quality of life in AIDS patients.
Keywords: HIV; anti-inflammatory action; iodine-lithium-α-dextrin; ILαD monotherapy; quality of life; AIDS patients; clinical efficacy; tolerability; safety; phlebitis; subfebrile fever.
International Journal of Biotechnology, 2007 Vol.9 No.3/4, pp.301 - 317
Published online: 27 Jun 2007 *Full-text access for editors Access for subscribers Purchase this article Comment on this article